Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2023 Annual Meeting
On November 6, Texas Retina Associates’ Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at AAO 2023, the annual meeting of the
read more
Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more
Dr. Kothari to Speak at Retina World Congress Young Retina Connect Event
On October 29, 2023, Texas Retina Associates’ Nikisha Kothari, MD, will serve as one of seven panelists for Retina World Congress’ (RWC) “Young Retina Connect,” a virtual, interactive event involving retina specialists
read more
New Treatment for Wet AMD and Diabetic Eye Disease Reduces Treatment Burden for Patients by Extending Dosing Intervals
On August 18, 2023, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept), a high-dose version of Eylea, for the treatment of several retinal conditions, including advanced neovascular age-related macular
read more
New Treatments Available for Geographic Atrophy
We know geographic atrophy (GA) can negatively impact patients’ quality of life and independence. While it still cannot be cured, Texas Retina is excited to finally have two new GA treatment options
read more
Getting to Know Diana Laura, MD
Board-certified ophthalmologist and retina specialist Diana M. Laura, MD, joined Texas Retina Associates in September 2022, and cares for patients in our Dallas Main, Rockwall and Wichita Falls offices. She completed her
read more
Dr. Abbey Publishes Case Report on Macular Hole Closure with Intravitreal Dexamethasone Implant
In the September 2023 issue of the peer-reviewed medical journal Ophthalmic Surgery, Lasers and Imaging Retina, Texas Retina’s Ashkan Abbey, MD, describes the use of a dexamethasone intravitreal implant to close a
read more New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more Dr. Abbey Publishes Research on Effectiveness of a Long-acting Injectable Steroid for Patients with Cystoid Macular Edema After Vitrectomy
Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan
read more
Inflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 18 – 24, 2023, as Inflammatory Eye Disease Awareness Week. There are a number of inflammatory eye conditions. The one we specialize in at Texas Retina Associates
read more